Last reviewed 2026-04-19 · How we verify

C326, IL-6 Inhibitory Avimer protein

Avidia · Phase 1 active Small molecule

C326, IL-6 Inhibitory Avimer protein is a Small molecule drug developed by Avidia. It is currently in Phase 1 development.

At a glance

Generic name	C326, IL-6 Inhibitory Avimer protein
Sponsor	Avidia
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

C326, IL-6 Inhibitory Avimer protein CI brief — competitive landscape report
C326, IL-6 Inhibitory Avimer protein updates RSS · CI watch RSS
Avidia portfolio CI

Frequently asked questions about C326, IL-6 Inhibitory Avimer protein

What is C326, IL-6 Inhibitory Avimer protein?

C326, IL-6 Inhibitory Avimer protein is a Small molecule drug developed by Avidia.

Who makes C326, IL-6 Inhibitory Avimer protein?

C326, IL-6 Inhibitory Avimer protein is developed by Avidia (see full Avidia pipeline at /company/avidia).

What development phase is C326, IL-6 Inhibitory Avimer protein in?

C326, IL-6 Inhibitory Avimer protein is in Phase 1.

Manufacturer: Avidia — full pipeline
Compare: C326, IL-6 Inhibitory Avimer protein vs similar drugs
Pricing: C326, IL-6 Inhibitory Avimer protein cost, discount & access